Medical Center for Digestive Diseases, Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Eur Rev Med Pharmacol Sci. 2021 Apr;25(7):2916-2926. doi: 10.26355/eurrev_202104_25545.
Recent studies have provided evidence that long noncoding RNA SNHG7 is highly expressed and associated with poor clinical outcomes in cancer patients. The meta-analysis is aimed to evaluate the prognostic value of SNHG7 across various cancers.
Eligible studies about prognosis and clinicopathological features of SNHG7 expression in all kinds of tumors were collected by searching the databases of PubMed, Web of Science, Embase, Cochrane Library from inception through August 13, 2020. Odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) from eligible studies were extracted and pooled to investigate the association between SNHG7 and survival or clinicopathology by STATA 16.0 software.
A total of 13 studies enrolling 1029 cancer patients met the inclusion criteria in this meta-analysis. Based on the results, over-expressed SNHG7 was associated with deeper tumor invasion (OR: 2.76; 95% CI: 1.98-3.86; p: 0.000), earlier lymphatic metastasis (OR: 4.22; 95% CI: 3.04-5.86; p: 0.000), more advanced tumor stage (OR: 3.49; 95% CI: 2.45-4.98; p: 0.000) and poor histologic grade (OR: 2.23; 95% CI: 1.33-3.74; p: 0.002), but not with sex, age, tumor size and distant metastasis. As for prognosis, patients with high expression of SNHG7 were more likely to have shorter overall survival (OS) (HR: 1.64; 95% CI: 1.38-1.94; p: 0.000) and disease-free survival (DFS) (HR: 1.37; 95% CI: 1.09-1.71; p: 0.006).
SNHG7 may serve as a novel biomarker in terms of predicting prognosis and clinicopathological characters in various human cancers.
最近的研究提供了证据，表明长链非编码 RNA SNHG7 在癌症患者中高度表达，并与不良临床结局相关。本荟萃分析旨在评估 SNHG7 在各种癌症中的预后价值。
通过检索 PubMed、Web of Science、Embase、Cochrane Library 数据库，收集了所有类型肿瘤中 SNHG7 表达的预后和临床病理特征的相关研究，检索时间截至 2020 年 8 月 13 日。使用 STATA 16.0 软件提取并合并来自合格研究的比值比（OR）和风险比（HR）及其 95%置信区间（CI），以探讨 SNHG7 与生存或临床病理之间的关系。
本荟萃分析共纳入 13 项研究，共纳入 1029 例癌症患者。结果表明，SNHG7 过表达与肿瘤侵袭深度更深（OR：2.76；95%CI：1.98-3.86；p：0.000）、淋巴转移更早（OR：4.22；95%CI：3.04-5.86；p：0.000）、肿瘤分期更高（OR：3.49；95%CI：2.45-4.98；p：0.000）和组织学分级更差（OR：2.23；95%CI：1.33-3.74；p：0.002）有关，但与性别、年龄、肿瘤大小和远处转移无关。至于预后，SNHG7 高表达的患者总体生存率（OS）（HR：1.64；95%CI：1.38-1.94；p：0.000）和无病生存率（DFS）（HR：1.37；95%CI：1.09-1.71；p：0.006）更短。
SNHG7 可能成为预测各种人类癌症预后和临床病理特征的新型生物标志物。
